SOUTH SAN FRANCISCO, Calif., April 2, 2020 /PRNewswire/ — ORIC Pharmaceuticals, Inc., a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Christ… […]
– HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline- Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating
PALO ALTO, Calif., April 1, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the deve… […]
– HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline- Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating
PALO ALTO, Calif., April 1, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the deve… […]
– HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline- Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating
PALO ALTO, Calif., April 1, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the deve… […]
– HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline- Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating
PALO ALTO, Calif., April 1, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the deve… […]
– HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline- Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating
PALO ALTO, Calif., April 1, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the deve… […]
SOUTH SAN FRANCISCO, Calif., April 1, 2020 /PRNewswire/ — Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on March 31, 2020, the Compensation Committee of the Board of Directors approved, effective as of March 31, 2020, the grant… […]
SAN FRANCISCO, March 30, 2020 /PRNewswire/ — ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management solutions today announced that a global biotechnology/chemical and pharmaceutical giant based in Europe has chosen ValGenes… […]
SOUTH SAN FRANCISCO, Calif., March 25, 2020 /PRNewswire/ — VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and central nervous system (CNS) diseases and di… […]
— Proceeds to Support Clinical Development of Immuno-oncology Therapeutic APX005M and Advancement of New Immunotherapeutic Antibodies into Clinical Evaluation —
SAN CARLOS, Calif., March 24, 2020 /PRNewswire/ — Apexigen, Inc., a clinical-stage bio… […]
© 2020 San Francisco Biotechnology Network
